Aspreva, a small biotech company has been working hard through clinical testing to get FDA approval for its CellCept drug. Currently in Phase III testing, the drug may offer real advantages for people suffering with lupus nephritis and pemphigus vulgaris. Unlike many other biotech's, Aspreva has actually run a profit for eight consecutive quarters. Freytag's appointment to head up the firm could be just the right medicine for the firm as it moves forward.
Freytag has worked on the business side on a number of different pharmaceutical related firms and he is also extremely well-versed in the scientific-side of the business as well. In his most recent executive position, which started back in 2000 and ended in late 2006, he was the President, CEO and Chairman of Myogen, Inc. another publicly-traded development-stage biopharmaceutical company. Under his tutelage, Myogen was acquired by Gilead Sciences. Freytag is also currently on the board of a number of biotech related firm's as well organizations. He was in fact recently appointed Chairman of the Board of Immunicon another development-stage publicly traded biotech. Prior to Myogen he worked for a number of big and small pharmaceutical related companies.
Expect more positive changes at Aspreva and keep a close eye on its Phase III testing results.
Update on Aspreva
BloggingStocks 7/18/07
No comments:
Post a Comment